The Pathogenesis of Superior Limbic Keratoconjunctivitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00167050
First received: September 12, 2005
Last updated: November 25, 2005
Last verified: June 2005
  Purpose

Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.


Condition
Superior Limbic Keratoconjunctivitis

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 10
Study Start Date: July 2005
Estimated Study Completion Date: June 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Superior limbic keratoconjunctivitis patients who receive conjunctiva resection

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167050

Contacts
Contact: Fung-Rong Hu, MD 886-2-23123456 ext 5189 fungrong@ha.mc.ntu.edu.tw
Contact: Yi-Chen Sun, MD 886-968195019 yichen.sun@msa.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Fung-Rong Hu, MD    886-2-23123456 ext 5189    fungrong@ha.mc.ntu.edu.tw   
Contact: Yi-Chen Sun, MD    886-968195019    yichen.sun@msa.hinet.net   
Principal Investigator: Fung-Rong Hu, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Fung-Rong Hu, MD National Taiwan University Hospital
  More Information

No publications provided by National Taiwan University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00167050     History of Changes
Other Study ID Numbers: 9461700634
Study First Received: September 12, 2005
Last Updated: November 25, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases

ClinicalTrials.gov processed this record on September 16, 2014